Larimar Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders

Ticker: LRMR · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form TypeDEF 14A
Filed DateApr 29, 2024
Risk Levellow
Pages15
Reading Time19 min
Key Dollar Amounts$161.6 million
Sentimentneutral

Sentiment: neutral

Topics: Annual Meeting, Proxy Statement, Virtual Meeting, Stockholder Vote, Larimar Therapeutics

TL;DR

<b>Larimar Therapeutics, Inc. invites stockholders to its virtual 2024 Annual Meeting on May 29, 2024.</b>

AI Summary

Larimar Therapeutics, Inc. (LRMR) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Larimar Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, at 11:00 a.m. Eastern Time. The meeting will be conducted exclusively in a virtual format, accessible online at meetnow.global/MN99LW9. Stockholders can participate and vote remotely, with no physical attendance option available. The company cites cost savings and reduced environmental impact as reasons for the virtual format. Michael Celano, Chief Financial Officer and Secretary, can be contacted at 484-414-2715 for voting inquiries.

Why It Matters

For investors and stakeholders tracking Larimar Therapeutics, Inc., this filing contains several important signals. The virtual format allows global participation and reduces operational costs for the company. Encouraging early voting ensures shareholder representation and facilitates meeting logistics.

Risk Assessment

Risk Level: low — Larimar Therapeutics, Inc. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would significantly alter the company's risk profile.

Analyst Insight

Stockholders should review the proxy materials and vote their shares prior to the May 29, 2024 meeting to ensure their voice is heard on company matters.

Key Numbers

  • May 29, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders date.)
  • 11:00 a.m. ET — Annual Meeting Time (2024 Annual Meeting of Stockholders time.)
  • 484-414-2715 — Contact Number (Phone number for voting inquiries.)

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
  • May 29, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
  • Michael Celano (person) — Chief Financial Officer and Secretary of Larimar Therapeutics, Inc.
  • Joseph Truitt (person) — Chairperson of the Board of Larimar Therapeutics, Inc.
  • Carole S. Ben-Maimon, M.D. (person) — Member of the Board of Larimar Therapeutics, Inc.
  • meetnow.global/MN99LW9 (url) — Internet address to access the virtual annual meeting.

FAQ

When did Larimar Therapeutics, Inc. file this DEF 14A?

Larimar Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Larimar Therapeutics, Inc. (LRMR).

Where can I read the original DEF 14A filing from Larimar Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Larimar Therapeutics, Inc..

What are the key takeaways from Larimar Therapeutics, Inc.'s DEF 14A?

Larimar Therapeutics, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: Larimar Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, at 11:00 a.m. Eastern Time.. The meeting will be conducted exclusively in a virtual format, accessible online at meetnow.global/MN99LW9.. Stockholders can participate and vote remotely, with no physical attendance option available..

Is Larimar Therapeutics, Inc. a risky investment based on this filing?

Based on this DEF 14A, Larimar Therapeutics, Inc. presents a relatively low-risk profile. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would significantly alter the company's risk profile.

What should investors do after reading Larimar Therapeutics, Inc.'s DEF 14A?

Stockholders should review the proxy materials and vote their shares prior to the May 29, 2024 meeting to ensure their voice is heard on company matters. The overall sentiment from this filing is neutral.

How does Larimar Therapeutics, Inc. compare to its industry peers?

Larimar Therapeutics, Inc. operates in the pharmaceutical preparations industry, focusing on developing treatments for rare diseases.

Are there regulatory concerns for Larimar Therapeutics, Inc.?

This filing is a standard proxy statement (DEF 14A) required under the Securities Exchange Act of 1934, detailing information for the annual stockholder meeting.

Risk Factors

  • Virtual Meeting Format [low — operational]: The company is holding its annual meeting virtually, which may present challenges for some stockholders to attend or participate fully.

Industry Context

Larimar Therapeutics, Inc. operates in the pharmaceutical preparations industry, focusing on developing treatments for rare diseases.

Regulatory Implications

This filing is a standard proxy statement (DEF 14A) required under the Securities Exchange Act of 1934, detailing information for the annual stockholder meeting.

What Investors Should Do

  1. Review the proxy statement for proposals to be voted on at the annual meeting.
  2. Vote your shares electronically or by phone before the May 29, 2024 meeting.
  3. Contact Michael Celano at 484-414-2715 with any questions regarding voting procedures.

Key Dates

  • 2024-05-29: 2024 Annual Meeting of Stockholders — Key date for stockholder participation and voting.
  • 2024-04-29: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, following the typical format for such filings.

Filing Stats: 4,643 words · 19 min read · ~15 pages · Grade level 13.4 · Accepted 2024-04-29 16:01:59

Key Financial Figures

  • $161.6 million — stock for net proceeds of approximately $161.6 million. Notice of Annual Meeting of Stockhol

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23 2023 SUMMARY COMPENSATION TABLE 23 PLEDGING AND HEDGING POLICIES 24 CLAWBACK POLICY 25 OUTSTANDING EQUITY AWARDS AT FISCAL 2023 YEAR-END 25 EMPLOYMENT AGREEMENTS 26 PAY VERSUS PERFORMANCE 27 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 31 INDEMNIFICATION AGREEMENTS 31 OTHER TRANSACTIONS 31 POLICIES AND PROCEDURES FOR RELATED PERSON TRANSACTIONS 31 EQUITY COMPENSATION PLAN INFORMATION 32 Notice of Annual Meeting of Stockholders and 2024 Proxy Statement|iv Table of Contents TABLE OF CONTENTS (continued)

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 33 ITEMS TO BE VOTED ON 36 PROPOSAL 1: ELECTION OF CLASS I DIRECTORS FOR A THREE-YEAR TERM EXPIRING AT THE 2027 ANNUAL MEETING OF STOCKHOLDERS 36 PROPOSAL 2: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS IN 2023 37 PROPOSAL 3: RATIFICATION OF APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE 2024 FISCAL YEAR 38 PROPOSAL 4: APPROVAL OF AN AMENDMENT TO OUR NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO REFLECT DELAWARE LAW PROVISIONS REGARDING OFFICER EXCULPATION 39 PROPOSAL 5: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE PROPOSAL 41 OTHER INFORMATION 42 OTHER MATTERS 42 REQUIREMENTS FOR SUBMISSION OF STOCKHOLDER PROPOSALS FOR NEXT YEARS ANNUAL MEETING 42 STOCKHOLDER COMMUNICATIONS TO THE BOARD 42 HOUSEHOLDING 43 AVAILABILITY OF MATERIALS 43 APPENDIX A: CERTIFICATE OF AMENDMENT OF NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 44 Notice of Annual Meeting of Stockholders and 2024 Proxy Statement|v Table of Contents PROXY STATEMENT This Proxy Statement, with the enclosed proxy card, is being furnished to stockholders of Larimar Therapeutics, Inc. (the Company) in connection with the solicitation by our Board of proxies to be voted at our Annual Meeting and at any postponements or adjournments thereof. The Annual Meeting will be held on Wednesday, May 29, 2024, at 11:00 a.m., Eastern Time via the Internet at meetnow.global/MN99LW9 . Notice of Annual Meeting of Stockholders and 2024 Proxy Statement|vi Table of Contents GENERAL INFORMATION ABOUT THE MEETING ATTENDING THE ANNUAL MEETING The Annual Meeting will be conducted virtually via live webcast, and there will not be a physical meeting location. We have adopted a virtual format for the

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.